RETRACTED ARTICLE: Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19
Adewunmi Akingbola, Adegbesan Abiodun Christopher, Kolade Adegoke, Courage Idahor, Petra Mariaria, Favour Peters, Raolat Adenike Salami, Olajide Ojo, Emmanuel Nwaeze, Owolabi Abdullahi, Joel Chuku
Abstract
This review examines Moderna's mRNA-1083 and Pfizer/BioNTech's mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna's mRNA-1083 showed superior immune responses, while Pfizer's mRNA-1020/1030 performed well but was slightly less effective against influenza B. These vaccines simplify immunization strategies, enhance protection, and emphasize the need for global vaccine equity to prevent future outbreaks.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Messenger RNADual (grammatical number)2019-20 coronavirus outbreakBiologyMedicineGeneGeneticsPhilosophyInternal medicineOutbreakLinguisticsDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchInfluenza Virus Research StudiesViral gastroenteritis research and epidemiology